Immunocore, a UK-based biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, has appointed Christina Coughlin as Chief Medical Officer. She takes responsibility for providing medical and regulatory leadership to the company's pre-clinical and clinical programmes.
Coughlin has experience in oncology drug development and expertise in both clinical development and translational medicine. She has more than a decade of industry experience at pharmaceutical and biotech companies.
Most recently, Coughlin was leading two early development programmes at Novartis in checkpoint inhibition and P13'kinase inhibition. She led the overall programme early development teams, including preclinical pharmacology, toxicology, clinical pharmacology, clinical development, biomarker development and regulatory work.
Prior to this she was International Project Team Leader at Morphotek Inc, the monoclonal antibody company acquired by Eisai Co in 2007, where she led the early clinical development team.
